

# MEDICAL POLICY – 8.01.21


## Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

BCBSA Ref. Policy: 8.01.21  
 Effective Date: May 1, 2018  
 Last Revised: Sept. 1, 2018  
 Replaces: N/A

RELATED MEDICAL POLICIES:	
7.01.50	Placental and Umbilical Cord Blood as a Source of Stem Cells
8.01.15	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
8.01.22	Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
8.01.24	Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults
8.01.25	Hematopoietic Cell Transplantation for Autoimmune Diseases
8.01.29	Hematopoietic Cell Transplantation for Hodgkin Lymphoma
8.01.511	Hematopoietic Cell Transplantation for Solid Tumors of Childhood
8.01.520	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
8.01.529	Hematopoietic Cell Transplantation for Non-Hodgkin Lymphomas
8.01.530	Hematopoietic Cell Transplantation for Primary Amyloidosis
8.01.531	Hematopoietic Cell Transplantation for Waldenstrom Macroglobulinemia
8.01.532	Hematopoietic Cell Transplantation in the Treatment of Germ-Cell Tumors

Select a hyperlink below to be directed to that section.

- [POLICY CRITERIA](#) | [CODING](#) | [RELATED INFORMATION](#)
- [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

### Introduction

Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are diseases of bone marrow and the blood cells they produce. These disorders can turn into a certain type of leukemia (acute myelocytic leukemia, or AML). A type of treatment called a hematopoietic stem cell transplant is sometimes used to treat these conditions.

Hematopoietic stem cells are cells that are made within the bone marrow and can develop into many different types of blood cells. In a hematopoietic stem cell transplant, stem cells can be taken from a donor and transplanted into the person with the MDS or MPN. When the stem cells are harvested from a donor, it is called an allogeneic hematopoietic stem cell transplant.

This policy discusses when a hematopoietic stem cell transplant may be medically necessary to treat myelodysplastic syndromes and myeloproliferative neoplasms.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

## Policy Coverage Criteria

Treatment	Medical Necessity
<b>Myeloablative allogeneic hematopoietic cell transplantation</b>	<p><b>Myeloablative allogeneic hematopoietic cell transplantation (allo-HCT) may be considered medically necessary as a treatment of:</b></p> <ul style="list-style-type: none"> <li>• Myelodysplastic syndromes (MDS)</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• Myeloproliferative neoplasms (MPN)</li> </ul>
<b>Reduced-intensity conditioning allogeneic hematopoietic cell transplantation</b>	<p><b>Reduced-intensity conditioning allo-HCT may be considered medically necessary as a treatment of:</b></p> <ul style="list-style-type: none"> <li>• Myelodysplastic syndromes</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• Myeloproliferative neoplasms in patients who, for medical reasons, would be unable to tolerate a myeloablative conditioning regimen</li> </ul>

## Myeloid Neoplasms

The myeloid neoplasms are categorized according to criteria developed by the World Health Organization (WHO). They are risk-stratified according to the International Prognostic Scoring System (IPSS).



## 2008 WHO Classification Scheme for Myeloid Neoplasms

- Acute myeloid leukemia (AML)
- Myelodysplastic syndromes (MDS)
- Myeloproliferative neoplasms (MPN)
  - Chronic myelogenous leukemia
  - Polycythemia vera
  - Essential thrombocythemia
  - Primary myelofibrosis
  - Chronic neutrophilic leukemia
  - Chronic eosinophilic leukemia, not otherwise categorized
  - Hypereosinophilic leukemia
  - Mast cell disease
  - MPNs, unclassifiable
- MDS/MPN
  - Chronic myelomonocytic leukemia
  - Juvenile myelomonocytic leukemia
  - Atypical chronic myeloid leukemia
  - MDS/MPN, unclassifiable
- Myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1
  - Myeloid neoplasms associate with PDGFRA rearrangement
  - Myeloid neoplasms associate with PDGFRB rearrangement
  - Myeloid neoplasms associate with FGFR1 rearrangement (8p11 myeloproliferative syndrome)

## 2008 WHO Classification of MDS

- Refractory anemia (RA)
- RA with ring sideroblasts (RARS)
- Refractory cytopenia with multilineage dysplasia (RCMD)
- RCMD with ring sideroblasts
- RA with excess blasts 1 and 2 (RAEB 1 and 2)
- Del 5q syndrome
- Unclassified MDS



## Risk Stratification of Myelodysplastic Syndromes

Risk stratification for MDS is performed using the IPSS (see [Table 1](#)). This system was developed after pooling data from 7 studies that used independent, risk-based prognostic factors. The prognostic model and the scoring system were based on blast count, degree of cytopenia, and blast percentage. Risk scores were weighted relative to their statistical power. This system is widely used to group patients into either low -risk and high-risk groups (see [Table 2](#)). The low-risk group includes low -risk and intermediate -1 IPSS groups; treatment goals in low-risk MDS patients are to improve quality of life and achieve transfusion independence. In the high-risk group, which includes intermediate -2 and high-risk IPSS groups, treatment goals are slowing disease progression to AML and improving survival. The IPSS is usually calculated at the time of diagnosis. The role of lactate dehydrogenase, marrow fibrosis, and  $\beta_2$ -microglobulin also should be considered after establishing the IPSS. If elevated, the prognostic category worsens by one category level.

**Table 1. IPSS: Myelodysplastic Syndrome Prognostic Variables**

Variable	0	0.5	1.0	1.5	2.0
Marrow blasts, %	<5%	5%-10%	–	11%-20%	21%-30%
Karyotype	Good	Intermediate	Poor		
Cytopenias	0/1	2/3	–	–	–

IPSS: International Prognostic Scoring System.

**Table 2. IPSS: Myelodysplastic Syndrome Clinical Outcomes**

Risk Group	Total Score	Median Survival, y	Time for 25% to Progress to AML
Low	0	5.7	9.4 years
Intermediate-1	0.5-1.0	3.5	3.3 years
Intermediate-2	1.5-2.0	1.2	1.12 years
High	$\geq 2.5$	0.4	0.2 years

AML: acute myelocytic leukemia. IPSS: International Prognostic Scoring System.



An updated 5-category IPSS has been proposed for prognosis in patients with primary MDS or secondary AML to account for chromosomal abnormalities frequently seen in MDS (Schanz et al, 2012). This system stratifies patients into 5 categories: very poor, poor, intermediate, good, and very good. There has also been an investigation into using the 5-category IPSS to better characterize risk in MDS.

Given the long natural history of MDS, allo-HCT is typically considered in patients with increasing numbers of blasts, signaling a possible transformation to acute myeloid leukemia (AML). Subtypes falling into this category include refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia.

Patients with refractory anemia with or without ringed sideroblasts may be considered candidates for allo-HCT when chromosomal abnormalities are present or the disorder is associated with the development of significant cytopenias (eg, neutrophils  $<500/\text{mm}^3$ , platelets  $<20,000/\text{mm}^3$ ).

Patients with MPNs may be considered candidates for allo-HCT when there is progression to myelofibrosis or toward acute leukemia. In addition, allo-HCT may be considered in patients with essential thrombocythemia with an associated thrombotic or hemorrhagic disorder. The use of allo-HCT should be based on the following criteria: cytopenias, transfusion dependence, increasing blast percentage over 5%, and age.

Some patients for whom a conventional myeloablative allo-HCT could be curative may be considered candidates for reduced-intensity conditioning (RIC) allo-HCT. They include patients whose age (typically  $>60$  years) or comorbidities (eg, liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status) preclude use of a standard myeloablative conditioning regimen. The ideal allogeneic donors are human leukocyte antigen (HLA)-identical siblings, matched at the HLA-A, B, and DR loci (6/6). Related donors mismatched at one locus are also considered suitable donors. A matched, unrelated donor identified through the National Marrow Donor Registry is typically the next option considered. Recently, there has been interest in haploidentical donors, typically a parent or a child of the patient, where usually there is sharing of only 3 of the 6 major histocompatibility antigens. Most patients will have such a donor; however, the risk of graft-versus-host disease (GVHD) and overall morbidity of the procedure may be severe, and experience with these donors is not as GVHD extensive as that with matched donors.

Clinical input suggests RIC allo-HCT may be considered for patients as follows:

## **MDS**

- IPSS intermediate-2 or high risk



- Red blood cell (RBC) transfusion dependence
- Neutropenia
- Thrombocytopenia
- High-risk cytogenetics
- Increasing blast percentage

### MPN

- Cytopenias
- Transfusion dependence
- Increasing blast percentage over 5%
- Age 60 to 65 years

## Coding

Code	Description
<b>CPT</b>	
38232	Bone marrow harvesting for transplantation; autologous
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
<b>HCPCS</b>	
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre and post transplant care in the global definition

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

## Related Information



## Consideration of Age

In this policy, RIC allogeneic HSCT may be considered medically necessary as a treatment of MPNs in patients who for medical reasons would be unable to tolerate a myeloablative conditioning regime. MPNs primarily occur in older individuals, with the majority of cases reported in patients aged 60 and older. HSCT is at present the only potentially curative therapy. Since direct, prospective clinical trials of outcomes are not available, clinical input was obtained. The clinical input supported the use of allogeneic HSCT using either a myeloablative or RIC regimens in patients when selection is guided by age and disease risk factors.

## Evidence Review

---

### Description

Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) refer to a heterogeneous group of clonal hematopoietic disorders with the potential to transform into acute myelocytic leukemia (AML). Allogeneic hematopoietic cell transplantation (allo-HCT) has been proposed as a curative treatment option for patients with these disorders.

### Background

#### *Myelodysplastic Syndromes*

Myelodysplastic syndromes (MDS) can occur as a primary (idiopathic) disease or can be secondary to cytotoxic therapy, ionizing radiation, or other environmental insult. Chromosomal abnormalities are seen in 40% to 60% of patients, frequently involving deletions of chromosome 5 or 7, or an extra chromosome as in trisomy 8. Most MDS diagnoses occur in individuals older than age 55-60 years, with an age-adjusted incidence of approximately 62% among individuals older than age 70 years. Patients succumb either to disease progression to acute myelocytic leukemia (AML) or to complications of pancytopenias. Patients with higher blast counts or complex cytogenetic abnormalities have a greater likelihood of progressing to AML than do other patients.



## MDS Classification and Prognosis

The French-American-British (FAB) system has been used to classify MDS into 5 subtypes: (1) refractory anemia (RA); (2) refractory anemia with ringed sideroblasts (RARS); (3) refractory anemia with excess blasts (RAEB); (4) refractory anemia with excess blasts in transformation; and (5) chronic myelomonocytic leukemia. However, the FAB system has been supplanted by that of the World Health Organization (WHO), which records the number of lineages in which dysplasia is seen (unilineage vs multilineage), separates the 5q- syndrome, and reduces the threshold maximum blast percentage for the diagnosis of MDS from 30% to 20% (see the [Policy Coverage Criteria](#) section for WHO classification scheme for myeloid neoplasms).

The most commonly used prognostic scoring system for MDS is the International Prognostic Scoring System (IPSS), which groups patients into 1 of 4 prognostic categories based on the number of cytopenias, cytogenetic profile, and the percentage of blasts in the bone marrow. This system underweights the clinical importance of severe, life-threatening neutropenia and thrombocytopenia in therapeutic decisions and does not account for the rate of change in critical parameters (eg, peripheral blood counts, blast percentage). However, the IPSS has been useful in comparative analysis of clinical trial results and its utility confirmed at many institutions. An updated 5-category IPSS has been proposed for prognosis in patients with primary MDS or secondary AML to account for chromosomal abnormalities frequently seen in MDS.<sup>1</sup> This system stratifies patients into 5 categories: very poor, poor, intermediate, good, and very good. There has been an investigation into using the 5-category IPSS to better characterize risk in MDS. A second prognostic scoring system incorporates the WHO subgroup classification that accounts for blast percentage, cytogenetics, and severity of cytopenias as assessed by transfusion requirements. The WHO Classification-based Prognostic Scoring System (WPSS) uses a 6-category system, which allows more precise prognostication of overall survival (OS) duration, as well as risk for progression to AML. This system, however, is not yet in widespread use in clinical trials.

## MDS Treatment

Treatment of non-progressing MDS has involved best supportive care, including red blood cell (RBC) and platelet transfusions and antibiotics. Active therapy was given only when MDS progressed to AML or resembled AML with severe cytopenias. An array of therapies are now available to treat MDS, including hematopoietic growth factors (eg, erythropoietin, darbepoetin, granulocyte colony-stimulating factor), transcriptional-modifying therapy (eg, U.S. Food and





Drug Administration [FDA]–approved hypomethylating agents, nonapproved histone deacetylase inhibitors), immunomodulators (eg, lenalidomide, thalidomide, antithymocyte globulin, cyclosporine A), low-dose chemotherapy (eg, cytarabine), and allo-HCT. Given the spectrum of treatments available, the goal of therapy must be decided upfront whether it is to improve anemia, thrombocytopenia, or neutropenia, to eliminate the need for red blood cell transfusion; to achieve complete remission, or to cure the disease.

Allo-HCT is the only approach with curative potential, but its use is governed by patient age, performance status, medical comorbidities, the patient’s risk preference, and severity of MDS at presentation.

### ***Chronic Myeloproliferative Neoplasms***

Chronic Myeloproliferative neoplasms (MPN) are clonal bone marrow stem-cell disorders; as a group, approximately 8400 MPN are diagnosed annually in the United States. Like MDS, MPN primarily occur in older individuals, with approximately 67% reported in patients aged 60 years and older.

MPN are characterized by the slow but progressive expansion of a clone of cells with the potential may evolve into a blast crisis similar to AML. They share a common stem cell-derived clonal heritage, with phenotypic diversity attributed to abnormal variations in signal transduction as the result of a spectrum of mutations that affect protein tyrosine kinases or related molecules. The unifying characteristic common to all MPNs is effective clonal myeloproliferation resulting in peripheral granulocytosis, thrombocytosis, or erythrocytosis that is devoid of dyserythropoiesis, granulocytic dysplasia, or monocytosis.

#### **MPN Classification**

In 2008, a new WHO classification scheme replaced the term chronic myeloproliferative disorder with the term myeloproliferative neoplasm. MPN are a subdivision of myeloid neoplasms that includes the 4 classic disorders: chronic myeloid leukemia (CML), polycythemia vera, essential thrombocytopenia, and primary myelofibrosis. The WHO classification also includes chronic neutrophilic leukemia, chronic eosinophilic leukemia/hypereosinophilic syndrome, mast cell disease, and MPNs unclassifiable.



## **MPN Treatment**

In indolent, nonprogressing cases, therapeutic approaches are based on relief of symptoms. Supportive therapy may include prevention of thromboembolic events. Hydroxyurea may be used in cases of high-risk essential thrombocytosis and polycythemia vera and intermediate- and high-risk primary myelofibrosis.

In 2011, the FDA approved the orally administered selective Janus kinase 1 and 2 inhibitor ruxolitinib for the treatment of intermediate- or high-risk myelofibrosis. Ruxolitinib has been associated with improved OS, spleen size, and symptoms of myelofibrosis when compared with placebo.<sup>2</sup> The COMFORT-II trial (2013) compared ruxolitinib with best available therapy in patients with intermediate- and high-risk myelofibrosis, and demonstrated improvements in spleen volume and OS.<sup>3</sup> In a randomized trial comparing ruxolitinib with best available therapy (including antineoplastic agents, most commonly hydroxyurea, glucocorticoids), with no therapy for treatment of myelofibrosis, Harrison et al (2012) reported improvements in spleen size and quality of life, but not OS.<sup>4</sup>

Myeloablative allo-HCT has been considered the only potentially curative therapy, but because most patients are of advanced age with attendant comorbidities, its use is limited to those who can tolerate often severe treatment-related adverse events of this procedure. However, the use of RIC for allo-HCT has extended the potential benefits of this procedure to selected individuals with these disorders.

## ***Hematopoietic Cell Transplantation (HCT)***

Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allo-HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naive” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in greater detail in a separate policy (see [Related Policies](#)).

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. However, immunologic compatibility between donor and patient is a critical factor for achieving a good outcome of allo-HCT. Compatibility is established by typing of human leukocyte antigen (HLA) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, -B, and -DR loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci.



## **Conventional Preparative Conditioning for HCT**

The conventional (“classical”) practice of allo-HCT involves administration of cytotoxic agents (eg, cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that develops after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered to be the potentially curative component, it may be overwhelmed by extant disease without the use of pre-transplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse effects. These effects include pre-engraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allo-HCT, immune suppressant drugs are required to minimize graft rejection and GVHD, which also increases susceptibility of the patient to opportunistic infections.

## **Reduced Intensity Conditioning (RIC) for Allo-HCT**

RIC refers to the pre-transplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative (MA) conditioning treatments. The goal of RIC is to reduce disease burden and to minimize as much as possible the associated treatment-related morbidity and nonrelapse mortality (NRM) in the period during which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of NRM and relapse due to residual disease. RIC regimens can be viewed as a continuum in their effects, from nearly totally myeloablative to minimally myeloablative with lymphoablation, and intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For the purposes of this Policy, the term “reduced-intensity conditioning” will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully myeloablative (conventional) regimens.



## Summary of Evidence

For individuals who have myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPN) who receive myeloablative conditioning allogeneic hematopoietic cell transplantation (allo-HCT), the evidence includes case series, which are often heterogeneous in terms of diseases included. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. Primarily uncontrolled, observational studies of HCT for MDS have reported a relatively large range of overall and progression-free survival rates, which reflect the heterogeneity in patient populations, conditioning regimens, and other factors. Reported estimates for 3- to 5-year overall survival of 40% to 50% are typical. For HCT for MPN, data are more limited. At least 1 comparative study of HCT for myelofibrosis has demonstrated improved survival with HCT compared with standard therapy. At present, HCT is the only potentially curative treatment option for patients with MDS and MPN. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have MDS or MPN who receive reduced-intensity conditioning (RIC) allo-HCT, the evidence includes primarily retrospective observational series. Relevant outcomes are overall survival, disease-specific survival, and treatment-related morbidity and mortality. Direct, prospective comparisons of outcomes after HCT with either myeloablative conditioning or RIC in either MDS or MPN are not available. Evidence from retrospective, nonrandomized comparisons has suggested that RIC may be used in patients who are older and have more comorbidities without significantly worsening overall survival. RIC appears to be associated with lower rates of nonrelapse mortality but higher cancer relapse than myeloablative HCT. At present, HCT is the only potentially curative treatment option for patients with MDS and MPN. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

## Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in [Table 3](#).

**Table 3. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
---------	------------	--------------------	-----------------



NCT No.	Trial Name	Planned Enrollment	Completion Date
<b>Ongoing</b>			
<a href="#">NCT01366612</a>	PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant	54	Aug 2018
<a href="#">NCT00739141</a>	Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematologic Malignancies	80	Aug 2018
<a href="#">NCT00176930</a>	Allogeneic Transplant for Hematological Malignancy	350	Dec 2017
<a href="#">NCT02581007</a>	Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies	30	Feb 2018
<a href="#">NCT00887068</a>	Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse	246	Apr 2018
<a href="#">NCT01471444<sup>a</sup></a>	A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intravenous Busulfan Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	250	Nov 2018
<a href="#">NCT00822393</a>	Clinical Phase III Trial Treosulfan-Based Conditioning Versus Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML or MDS Considered Ineligible to Standard Conditioning Regimens	960	Mar 2019
<a href="#">NCT02626715</a>	Reduced Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HCT in AML/MDS	16	Sep 2019
<a href="#">NCT01760655</a>	Reduced Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients with High-Risk Hematologic Malignancies	50	Jan 2020
<a href="#">NCT02757989</a>	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Low Risk	105	Apr 2021

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.



## Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 2 academic medical center specialists while this policy was under review in 2009. There was consensus among reviewers that reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) was of value in patients with myelodysplastic syndromes and myeloproliferative neoplasms who would be medically unable to tolerate a myeloablative HCT.

## Practice Guidelines and Position Statements

### *National Comprehensive Cancer Network Guidelines*

Current National Comprehensive Cancer Network (NCCN) clinical practice guidelines for myelodysplastic syndromes (MDS; v.1.2018) make the following recommendation about hematopoietic cell transplantation (HCT) in general<sup>48</sup>:

For patients who are transplant candidates, the first choice of a donor has remained an HLA [human leukocyte antigen]-matched sibling, although results with HLA-matched unrelated donors have improved to levels comparable to those obtained with HLA-matched siblings. With the increasing use of cord blood or HLA-haploidentical related donors, HCT has become a viable option for many patients. High-dose conditioning is typically used for younger patients, whereas RIC [reduced-intensity conditioning] for HCT is generally the strategy in older individuals.

Specific NCCN guidelines related to HCT for MDS are outlined in [Table 4](#).<sup>48</sup>

**Table 4: Guidelines for Allo-HCT for Myelodysplastic Syndromes**

Prognostic Category	Recommendations for HCT
IPSS low/intermediate-1 <b>OR</b>	<ul style="list-style-type: none"><li>Consider allo-HCT for patients who have clinically relevant thrombocytopenia or neutropenia or increased marrow blasts, with</li></ul>



Prognostic Category	Recommendations for HCT
IPSS-R very low, low, intermediate <b>OR</b> WPSS very low, low, intermediate	disease progression or no response after azacitidine/decitabine or immunosuppressive therapy <ul style="list-style-type: none"> <li>Consider allo-HCT for patients who have symptomatic anemia with no 5q deletion, with serum erythropoietin level &gt;500 mU/mL, with poor probability of response to immunosuppressive therapy, and no response or intolerance to azacitidine/decitabine or immunosuppressive therapy</li> </ul>
IPSS intermediate-2, high <b>OR</b> IPSS-R intermediate, high, very high <b>OR</b> WPSS high, very high	<ul style="list-style-type: none"> <li>Recommend allo-HCT if a high-intensity therapy candidate and transplant candidate and donor stem cell source is available</li> </ul>

allo: allogeneic; HCT: hematopoietic cell transplantation; IPSS: International Prognostic Scoring System; WPSS: WHO Classification-based Prognostic Scoring System.

NCCN developed new guidelines for myeloproliferative neoplasms (MPN) in 2017 (v.2.2017).<sup>49</sup> **Table 5** summarizes the NCCN recommendations (v.2.2018) on the use of allo-HCT for the treatment of myeloproliferative neoplasms (MPN).<sup>49</sup> The guidelines note that selection of allo-HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver.

**Table 5: Guidelines for Allo-HCT for Myeloproliferative Neoplasms**

Prognostic Category	Recommendations for Allo-HCT
Intermediate risk – 1 myelofibrosis IPSS=1 DIPSS-Plus=1 DIPSS=1 or 2	<ul style="list-style-type: none"> <li>Consider observation or ruxolitinib if symptomatic or allo-HCT</li> <li>Evaluation for allo-HCT is recommended for patients with low platelet counts or complex cytogenetics</li> </ul>
Intermediate risk – 2 myelofibrosis IPSS=2 DIPSS-Plus=2 or 3 DIPSS=3 or 4 High-risk myelofibrosis IPSS>3 DIPSS-Plus=4 to 6 DIPSS=5 or 6	<ul style="list-style-type: none"> <li>Consider allo-HCT immediately or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant</li> <li>Evaluation for allo-HCT is recommended for patients with low platelet counts or complex cytogenetics</li> </ul>
Disease progression to advanced stage/AML	<ul style="list-style-type: none"> <li>Induce remission with hypomethylating agents or intensive induction chemotherapy followed by allo-HCT</li> </ul>



allo: allogeneic; AML: acute myeloid leukemia; DIPSS: Dynamic International Prognostic Scoring System; HCT: hematopoietic cell transplantation; IPSS: International Prognostic Scoring System

### *American Society for Blood and Marrow Transplantation*

In 2015, the American Society for Blood and Marrow Transplantation (ASBMT) published guidelines on indications for HCT, based on the recommendations of a multiple-stakeholder task force.<sup>50</sup> **Table 6** summarizes categorizations for allo-HCT.

**Table 6. Recommendations for the Use of HCT to Treat Myelodysplastic Syndromes, Myelofibrosis, and Myeloproliferative Neoplasms**

<b>Indication</b>	<b>Recommendation</b>
<b>Myelodysplastic syndromes</b>	
Low/intermediate-1 risk	Standard of care, clinical evidence available (large clinical trials are not available; however, sufficiently large cohort studies have shown efficacy with “acceptable risk of morbidity and mortality”)
Intermediate-2/high risk	Standard of care (“well defined and generally supported by evidence in the form of high quality clinical trials and/or observational studies”)
<b>Myelofibrosis and myeloproliferative neoplasms</b>	
Primary, low risk	Standard of care (“well defined and generally supported by evidence in the form of high quality clinical trials and/or observational studies”)
Primary, intermediate/high risk	Standard of care (“well defined and generally supported by evidence in the form of high quality clinical trials and/or observational studies”)
Secondary	Standard of care (“well defined and generally supported by evidence in the form of high quality clinical trials and/or observational studies”)
Hypereosinophilic syndromes, refractory	Standard of care, rare indication (clinical trials and observational studies are not feasible due to low incidence; small cohorts have shown efficacy with “acceptable risk of morbidity and mortality”)

### *European Blood and Marrow Transplantation Group and European LeukemiaNet*

In 2015, the European Blood and Marrow Transplantation and European LeukemiaNet Group published recommendations for the use of allo-HCT in primary myelofibrosis and for pre- and





posttransplant management and donor selection.<sup>51</sup> Recommendations related to the selection of patients for allo-HCT included:

- “All patients with intermediate-2 or high-risk disease according to IPSS, DIPSS [Dynamic International Prognostic Scoring System], or DIPSS+, and age < 70 years, should be considered potential candidates for allo-SCT [stem cell transplant].”
- “Patients with intermediate-1-risk disease and age <65 years should be considered candidates for allo-SCT if they present with either refractory, transfusion-dependent anemia or a percentage of blasts in PB [peripheral blood] >2%, or adverse cytogenetics (as defined by the DIPSS+ classification).”
- “Patients with low-risk disease should not undergo allo-SCT. They should be monitored and evaluated for transplantation when disease progression occurs.”
- “Patients in blast transformation (blasts in PB or in BM [bone marrow] or both equal to or >20%) are not good candidates for allo-SCT. They should receive debulking therapy and be reconsidered for transplant after achieving a partial or complete remission of leukemia.”
- “Although the use of molecular risk classification for the identification of candidates for allo-SCT among intermediate-1- risk patients deserves further clinical validation, patients in this risk category who are triple negative (that is, JAKV617F, CALR, and MPL negative) or ASXL1 positive, or both, should be considered for allo-SCT.”

## Medicare National Coverage

There is a national coverage determination for stem cell transplantation (110.23; formerly 110.81),<sup>52</sup> portions of which are highlighted below:

### “B. Nationally Covered Indications

#### I. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

- a. ...Treatment of leukemia, leukemia in remission, or aplastic anemia when it is reasonable and necessary,
- b. ...Treatment of severe combined immunodeficiency disease (SCID) and for the treatment of Wiskott-Aldrich syndrome.
- c. ...Treatment of Myelodysplastic Syndromes (MDS) pursuant to Coverage with Evidence Development (CED) in the context of a Medicare-approved, prospective clinical study.



Medicare payment for these beneficiaries will be restricted to patients enrolled in an approved clinical study.

- d. Effective ... January 27, 2016, allogeneic HSCT for multiple myeloma is covered by Medicare only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma, and participating in an approved prospective clinical study that meets the criteria below. There must be appropriate statistical techniques to control for selection bias and confounding by age, duration of diagnosis, disease classification, International Myeloma Working Group (IMWG) classification, ISS stage, comorbid conditions, type of preparative/conditioning regimen, graft vs. host disease (GVHD) prophylaxis, donor type and cell source....
- e. Effective ... January 27, 2016, allogeneic HSCT for myelofibrosis (MF) is covered by Medicare only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF and participating in an approved prospective clinical study. All Medicare approved studies must use appropriate statistical techniques in the analysis to control for selection bias and potential confounding by age, duration of diagnosis, disease classification, DIPSSplus score, comorbid conditions, type of preparative/conditioning regimen, graft vs. host disease (GVHD) prophylaxis, donor type and cell source....
- f. Effective ... January 27, 2016, allogeneic HSCT for sickle cell disease (SCD) is covered by Medicare only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study....”

## Regulatory Status

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

## References



1. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. *J Clin Oncol*. Mar 10 2012;30(8):820-829. PMID 22331955
2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med*. Mar 1 2012;366(9):799-807. PMID 22375971
3. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. *Blood*. Dec 12 2013;122(25):4047-4053. PMID 24174625
4. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med*. Mar 01 2012;366(9):787-798. PMID 22375970
5. Kasner MT, Luger SM. Update on the therapy for myelodysplastic syndrome. *Am J Hematol*. Mar 2009;84(3):177-186. PMID 19195035
6. Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. *Bone Marrow Transplant*. Apr 2009;43(8):597-609. PMID 19252532
7. Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. *Biol Blood Marrow Transplant*. Feb 2009;15(2):137-172. PMID 19167676
8. Koenecke C, Gohring G, de Wreede LC, et al. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. *Haematologica*. Mar 2015;100(3):400-408. PMID 25552702
9. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. *Semin Hematol*. Jan 2008;45(1):49-59. PMID 18179969
10. Blaise D, Vey N, Faucher C, et al. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. Apr 2007;92(4):533-541. PMID 17488664
11. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. *Haematologica*. Nov 2006;91(11):1513-1522. PMID 17082009
12. Huisman C, Meijer E, Petersen EJ, et al. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. *Biol Blood Marrow Transplant*. Feb 2008;14(2):181-186. PMID 18215778
13. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. *Ann Hematol*. Jun 2003;82(6):336-342. PMID 12728337
14. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. *Biol Blood Marrow Transplant*. Feb 2008;14(2):246-255. PMID 18215785
15. Martino R, Caballero MD, Perez-Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. *Blood*. Sep 15 2002;100(6):2243-2245. PMID 12200391
16. Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. *Hematology Am Soc Hematol Educ Program*. Nov 2007:355-362. PMID 18024651
17. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. *J Clin Oncol*. Dec 20 2005;23(36):9387-9393. PMID 16314618



18. Valcarcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. *Curr Opin Oncol*. Nov 2007;19(6):660-666. PMID 17906468
19. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. *J Clin Oncol*. Feb 01 2008;26(4):577-584. PMID 18086801
20. Zeng W, Huang L, Meng F, et al. Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review. *Int J Clin Exp Med*. Jan 2014;7(11):4357-4368. PMID 25550955
21. Aoki K, Ishikawa T, Ishiyama K, et al. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. *Br J Haematol*. Feb 2015;168(3):463-466. PMID 25228239
22. Kim H, Lee JH, Joo YD, et al. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. *Ann Hematol*. Sep 2012;91(9):1459-1469. PMID 22526363
23. Akhtari M. When to treat myelodysplastic syndromes. *Oncology (Williston Park)*. May 2011;25(6):480-486. PMID 21717901
24. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? *Blood*. Dec 2 2010;116(23):4762-4770. PMID 20702782
25. Giralt SA, Horowitz M, Weisdorf D, et al. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. *J Clin Oncol*. Feb 10 2011;29(5):566-572. PMID 21220586
26. Deeg HJ, Bartenstein M. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status. *Arch Immunol Ther Exp (Warsz)*. Feb 2012;60(1):31-41. PMID 22143157
27. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. *Am J Hematol*. Jul 2012;87(7):692-701. PMID 22696212
28. Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. *Blood*. Jun 14 2012;119(24):5632-5639. PMID 22504927
29. Basquiera AL, Pizzi S, Correas AG, et al. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina. *Pediatr Blood Cancer*. Jan 2015;62(1):153-157. PMID 25264233
30. Boehm A, Sperr WR, Kalhs P, et al. Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. *Wien Klin Wochenschr*. Jan 2014;126(1-2):23-29. PMID 24249320
31. Damaj G, Mohty M, Robin M, et al. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. *Biol Blood Marrow Transplant*. Sep 2014;20(9):1349-1355. PMID 24838178
32. Di Stasi A, Milton DR, Poon LM, et al. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. *Biol Blood Marrow Transplant*. Dec 2014;20(12):1975-1981. PMID 25263628
33. Onida F, Brand R, van Biezen A, et al. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. *Haematologica*. Oct 2014;99(10):1582-1590. PMID 25085359
34. Oran B, Kongtim P, Popat U, et al. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. Oct 2014;20(10):1618-1625. PMID 24953017



35. Yoshimi A, Strahm B, Baumann I, et al. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. *Biol Blood Marrow Transplant.* Mar 2014;20(3):425-429. PMID 24316460
36. Basquiera AL, Rivas MM, Remaggi G, et al. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO). *Hematology.* Apr 2016;21(3):162-169. PMID 26147089
37. Symeonidis A, van Biezen A, de Wreede L, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Br J Haematol.* Jul 26 2015;171(2):239-246. PMID 26212516
38. Pohlen M, Groth C, Sauer T, et al. Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (60 years). *Bone Marrow Transplant.* Nov 2016;51(11):1441-1448. PMID 27295269
39. Heidenreich S, Ziagkos D, de Wreede LC, et al. Ilogeneic stem cell transplantation for patients age  $\geq$  70 years with myelodysplastic syndrome: a retrospective study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. *Biol Blood Marrow Transplant.* Jan 2017;23(1):44-52. PMID 27720995
40. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. *J Clin Oncol.* Feb 10 2011;29(5):573-582. PMID 21220604
41. McLornan DP, Mead AJ, Jackson G, et al. Allogeneic stem cell transplantation for myelofibrosis in 2012. *Br J Haematol.* May 2012;157(4):413-425. PMID 22463701
42. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. *Biol Blood Marrow Transplant.* Mar 2010;16(3):358-367. PMID 19879949
43. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant.* Jan 2014;20(1):89-97. PMID 24161923
44. Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. *Blood.* May 21 2015;125(21):3347-3350; quiz 3364. PMID 25784679
45. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood.* Dec 17 2009;114(26):5264-5270. PMID 19812383
46. Gupta V, Kroger N, Aschan J, et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. *Bone Marrow Transplant.* Sep 2009;44(5):317-320. PMID 19234505
47. Abelson J, Merup M, Birgegard G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. *Bone Marrow Transplant.* Mar 2012;47(3):380-386. PMID 21552298
48. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/mds.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf) Accessed May 2018.
49. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms, Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/mpn.pdf](https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf) Accessed May 2018.
50. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* Nov 2015;21(11):1863-1869. PMID 26256941
51. Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. *Leukemia.* Nov 2015;29(11):2126-2133. PMID 26293647



52. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Stem Cell Transplantation Formerly 110.8.1 (110.23). 2016; [https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=366&ncdver=1&DocID=110.23&list\\_type=ncd&bc=gAAAAgAAAAAA%3d%3d&](https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=366&ncdver=1&DocID=110.23&list_type=ncd&bc=gAAAAgAAAAAA%3d%3d&) Accessed May 2018.

## History

Date	Comments
02/01/00	Add to Therapy Section - New Policy. Policy represents revision of 7.03.10 to focus on myelodysplasia and myelofibrosis. New policy statement on HDC for myelofibrosis.
11/12/02	Replace policy - Policy reviewed with no criteria changes.
07/13/04	Replace policy - Policy reviewed with literature; policy statement also now includes "mini-transplant." References added; cross-reference to BC.8.01.38 on mini-transplants added.
07/12/05	Replace policy - Policy reviewed with literature search; no change in policy statement. No further review scheduled.
02/06/06	Codes updated - No other changes.
06/02/06	Disclaimer and Scope Updates - No other changes.
10/09/07	Replace policy - Policy updated with literature review. Status changed from AR to BC. References added. No change in policy statement.
11/12/07	Codes updated - CPT code 86817 removed as directed by RPIW.
05/13/08	Cross Reference Update - No other changes
03/10/09	Replace policy - Policy updated with literature search. Minor terminology changes to policy statements; the intent of the policy statements remain unchanged. Additional policy statements include Reduced intensity conditioning allogeneic SCT is considered investigational as a treatment of myeloproliferative disorders and myelodysplastic syndrome. References and codes added. "High-Dose Chemotherapy" removed from the title and throughout the body of the policy and "myeloproliferative" diseases added to the policy title.
12/08/09	Code Update - 86817 code added back to the policy.
02/09/10	Code Update - New 2010 codes added.
03/08/11	Replace policy - Policy updated with literature search, reference numbers 14-17 added. Myeloproliferative Disorders" replaced with "Myeloproliferative Neoplasms" in title and text. Policy statements revised to indicate that RIC HCT, previously investigational, may now be considered medically necessary as a treatment of myelodysplastic syndrome and myeloproliferative neoplasms in patients who for medical reasons would be unable to tolerate a myeloablative conditioning regimen. Reviewed and recommended



Date	Comments
	by OAP in February 2011.
10/19/11	Related Policies updated; links refreshed.
01/06/12	Replace policy – Policy updated with literature search; references 15-18 and 20 added. Policy statements unchanged. ICD-10 codes added.
01/24/12	Code 38232 added.
02/09/12	CPT code 38204 was removed from the policy.
06/20/12	Minor update: Related Policies updated; 8.01.17 replaced 8.01.507 effective June 12, 2012.
08/01/12	Update Related Policies Titles: 8.01.17, 8.01.22, 8.01.30, 8.01.35, and 8.01.520. Removed Related Policy 8.01.38 as it was archived.
10/01/12	Update Coding Section – ICD-10 codes are now effective 10/01/2014.
01/29/13	Replace policy. Title revised with addition of the word “Hematopoietic”. Policy rationale updated based on a literature review through September 2012. Reference 26 added; others renumbered or removed. Policy statements unchanged.
09/30/13	Update Related Policies. Change title to 8.01.31.
10/18/13	Update Related Policies. Change title to 8.01.17.
01/21/14	Replace policy. Policy updated with literature search through October 8, 2013; reference 14 added. Policy statements unchanged. CPT code 38230 removed from policy; it does not apply.
02/27/14	Update Related Policies. Change title to 8.01.30.
03/21/14	Update Related Policies. Add 8.01.15 and delete 8.01.514.
04/18/14	Update Related Policies. Remove 8.01.20 and add 8.01.529.
06/24/14	Update Related Policies. Remove 8.01.35, 8.01.42 and 8.01.54, then add 8.01.530, 8.01.531 and 8.01.532.
12/03/14	Update Related Policies. Remove 8.01.21 and 8.01.26.
01/28/15	Annual Review. Policy updated with literature review through September 30, 2014. References 1-3, 5-6, 26-32, and 37 added. Policy statements unchanged. Remove ICD-9 and ICD-10 diagnosis codes; these are not utilized in policy adjudication.
02/19/15	Update Related Policies. Remove 8.01.30.
05/01/16	Annual Review, approved April 12, 2016. Policy updated with literature review through October 27, 2015. References 1, 8, 21-22, 36-38, 43, and 48 added. Policy statements unchanged. Update effective May 1, 2016.
09/01/16	Update Related Policies. Remove 8.01.27 as it was archived.
09/30/16	Coding Update. Remove CPT 86817 from coding section.



Date	Comments
11/04/16	Coding update. Removed codes that are transplant benefit related.
04/01/17	Annual Review, approved March 14, 2017. Policy name changed to Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy updated with literature review through November 7, 2016; references 37-38 and 49-50 added. Changed "hematopoietic stem cell transplantation" to "hematopoietic cell transplantation" per NCCN terminology change. Policy statements unchanged.
08/01/17	Updated title of Related Policy 8.01.511.
11/10/17	Policy moved to new format, no changes to policy statement.
05/01/18	Annual Review, approved April 3, 2018. Policy updated with literature review through November 2017; references updated. Removed investigational policy statements.
09/01/18	Minor update. Re-added Consideration of Age information, which was inadvertently removed during a previous update.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.





**Discrimination is Against the Law**

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:

- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Civil Rights Coordinator - Complaints and Appeals  
PO Box 91102, Seattle, WA 98111  
Toll free 855-332-4535, Fax 425-918-5592, TTY 800-842-5357  
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services  
200 Independence Avenue SW, Room 509F, HHH Building  
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)  
Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

**Getting Help in Other Languages**

**This Notice has Important Information.** This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

**አማርኛ (Amharic):**

ይህ ማስታወቂያ አስፈላጊ መረጃ ይዟል። ይህ ማስታወቂያ ስለ ማመልከቻዎ ወይም የ Premera Blue Cross ሽፋን አስፈላጊ መረጃ ሊኖረው ይችላል። በዚህ ማስታወቂያ ውስጥ ቁልፍ ቀናት ሊኖሩ ይችላሉ። የጤና ሽፋንዎን ለመጠበቅና በአስፋፈል እርዳታ ለማግኘት በተውሰኑ የጊዜ ገደቦች እርምጃ መውሰድ ይገባዎት ይሆናል። ይህን መረጃ እንዲያገኙ እና የለምንም ክፍያ በቋንቋዎ እርዳታ እንዲያገኙ መሰታ አለዎት። በስልክ ቁጥር 800-722-1471 (TTY: 800-842-5357) ይደውሉ።

**العربية (Arabic):**

يحتوي هذا الإشعار على معلومات هامة. قد يحوي هذا الإشعار معلومات مهمة بخصوص طلبك أو التغطية التي تزيد الحصول عليها من خلال Premera Blue Cross. قد تكون هناك تواريخ مهمة في هذا الإشعار. وقد تحتاج لاتخاذ إجراء في تاريخ معينه للحفاظ على تغطيتك الصحية أو المساعدة في دفع التكاليف. يحق لك الحصول على هذه المعلومات والمساعدة بلغتك دون تكبد أية تكلفة. اتصل بـ 800-722-1471 (TTY: 800-842-5357)

**中文 (Chinese):**

**本通知有重要的訊息。**本通知可能有關於您透過 Premera Blue Cross 提交的申請或保險的重要訊息。本通知內可能有重要日期。您可能需要在截止日期之前採取行動，以保留您的健康保險或者費用補貼。您有權利免費以您的母語得到本訊息和幫助。請撥電話 800-722-1471 (TTY: 800-842-5357)。

**Oromoo (Cushite):**

**Beeksisni kun odeeffannoo barbaachisaa qaba.** Beeksisti kun sagantaa yookan karaa Premera Blue Cross tiin tajaajila keessan ilaalchisee odeeffannoo barbaachisaa qabaachuu danda'a. Guyyaawwan murteessaa ta'an beeksisa kana keessatti ilaalaa. Tarii kaffaltiidhaan deeggaramuuf yookan tajaajila fayyaa keessaniif guyyaa dhumaa irratti wanti raawwattan jiraachuu danda'a. Kaffaltii irraa bilisa haala ta'een afaan keessaniin odeeffannoo argachuu fi deeggarsa argachuuf mirga ni qabaattu. Lakkoofsa bilbilaa 800-722-1471 (TTY: 800-842-5357) tii bilbilaa.

**Français (French):**

**Cet avis a d'importantes informations.** Cet avis peut avoir d'importantes informations sur votre demande ou la couverture par l'intermédiaire de Premera Blue Cross. Le présent avis peut contenir des dates clés. Vous devez peut-être prendre des mesures par certains délais pour maintenir votre couverture de santé ou d'aide avec les coûts. Vous avez le droit d'obtenir cette information et de l'aide dans votre langue à aucun coût. Appelez le 800-722-1471 (TTY: 800-842-5357).

**Kreyòl ayisyen (Creole):**

**Avi sila a gen Enfòmasyon Enpòtan ladann.** Avi sila a kapab genyen enfòmasyon enpòtan konsènan aplikasyon w lan oswa konsènan kouvèti asirans lan atravè Premera Blue Cross. Kapab genyen dat ki enpòtan nan avi sila a. Ou ka gen pou pran kèk aksyon avan sèten dat limit pou ka kenbe kouvèti asirans sante w la oswa pou yo ka ede w avèk depans yo. Se dwa w pou resewva enfòmasyon sa a ak asistans nan lang ou pale a, san ou pa gen pou peye pou sa. Rele nan 800-722-1471 (TTY: 800-842-5357).

**Deutsche (German):**

**Diese Benachrichtigung enthält wichtige Informationen.** Diese Benachrichtigung enthält unter Umständen wichtige Informationen bezüglich Ihres Antrags auf Krankenversicherungsschutz durch Premera Blue Cross. Suchen Sie nach eventuellen wichtigen Terminen in dieser Benachrichtigung. Sie könnten bis zu bestimmten Stichtagen handeln müssen, um Ihren Krankenversicherungsschutz oder Hilfe mit den Kosten zu behalten. Sie haben das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Rufen Sie an unter 800-722-1471 (TTY: 800-842-5357).

**Hmoob (Hmong):**

**Tsawb ntawv tshaj xo no muaj cov ntshiab lus tseem ceeb.** Tej zaum tsawb ntawv tshaj xo no muaj cov ntshiab lus tseem ceeb txog koj daim ntawv thov kev pab los yog koj qhov kev pab cuam hnuv ntawm Premera Blue Cross. Tej zaum muaj cov hnuv tseem ceeb uas sau rau hauv daim ntawv no. Tej zaum koj kuj yuav tau ua qee yam uas peb kom koj ua tsis pub dhau cov caij nyuog uas teev tseg rau hauv daim ntawv no mas koj thiaj yuav tau txais kev pab cuam kho mob los yog kev pab them tej nqi kho mob ntawd. Koj muaj cai kom lawv muab cov ntshiab lus no uas tau muab sau ua koj hom lus pub dawb rau koj. Hu rau 800-722-1471 (TTY: 800-842-5357).

**Iloko (Ilocano):**

**Daytoy a Pakdaar ket naglaon iti Napateg nga Impormasion.** Daytoy a pakdaar mabalin nga adda ket naglaon iti napateg nga impormasion maipanggep iti aplikasyonyo wenna coverage babaen iti Premera Blue Cross. Daytoy ket mabalin dagiti importante a petsa iti daytoy a pakdaar. Mabalin nga adda rumbeng nga aramidenyo nga addang sakbay dagiti partikular a naituding nga aldaw tapno mapagtalinaedyo ti coverage ti salun-ato wenna tulong kadagiti gastos. Adda karbenganyo a mangala iti daytoy nga impormasion ken tulong iti bukodyo a pagsasao nga awan ti bayadanyo. Tumawag iti numero nga 800-722-1471 (TTY: 800-842-5357).

**Italiano (Italian):**

**Questo avviso contiene informazioni importanti.** Questo avviso può contenere informazioni importanti sulla tua domanda o copertura attraverso Premera Blue Cross. Potrebbero esserci date chiave in questo avviso. Potrebbe essere necessario un tuo intervento entro una scadenza determinata per consentirti di mantenere la tua copertura o sovvenzione. Hai il diritto di ottenere queste informazioni e assistenza nella tua lingua gratuitamente. Chiama 800-722-1471 (TTY: 800-842-5357).

**日本語 (Japanese):**

この通知には重要な情報が含まれています。この通知には、Premera Blue Cross の申請または補償範囲に関する重要な情報が含まれている場合があります。この通知に記載されている可能性がある重要な日付をご確認ください。健康保険や有料サポートを維持するには、特定の期日までに行動を取らなければならない場合があります。ご希望の言語による情報とサポートが無料で提供されます。800-722-1471 (TTY: 800-842-5357)までお電話ください。

**한국어 (Korean):**

본 통지서에는 중요한 정보가 들어 있습니다. 즉 이 통지서는 귀하의 신청에 관하여 그리고 Premera Blue Cross 를 통한 커버리지에 관한 정보를 포함하고 있을 수 있습니다. 본 통지서에는 핵심이 되는 날짜들이 있을 수 있습니다. 귀하의 건강 커버리지를 계속 유지하거나 비용을 절감하기 위해서 일정한 마감일까지 조치를 취해야 할 필요가 있을 수 있습니다. 귀하의 이러한 정보와 도움을 귀하의 언어로 비용 부담없이 얻을 수 있는 권리가 있습니다. 800-722-1471 (TTY: 800-842-5357) 로 전화하십시오.

**ລາວ (Lao):**

ແຈ້ງການນີ້ມີຂໍ້ມູນສໍາຄັນ. ແຈ້ງການນີ້ອາດຈະມີຂໍ້ມູນສໍາຄັນກ່ຽວກັບຄໍາຮ້ອງສະໝັກ ຫຼື ຄວາມຄົມຄອງປະກັນໄພຂອງທ່ານຜ່ານ Premera Blue Cross. ອາດຈະມີວັນທີ່ສໍາຄັນໃນແຈ້ງການນີ້. ທ່ານອາດຈະຈຳເປັນຕ້ອງດໍາເນີນການຕາມກຳນົດ ເວລາສະເພາະເພື່ອຮັກສາຄວາມຄົມຄອງປະກັນສະພາບ ຫຼື ຄວາມຊ່ວຍເຫຼືອເວັ້ນເວົ້ອງຄ່າໃຊ້ຈ່າຍຂອງທ່ານໄດ້. ທ່ານມີສິດໄດ້ຮັບຂໍ້ມູນນີ້ ແລະ ຄວາມຊ່ວຍເຫຼືອເປັນພາສາຂອງທ່ານໂດຍບໍ່ເສຍຄ່າ. ໃຫ້ໃບທາ 800-722-1471 (TTY: 800-842-5357).

**ភាសាខ្មែរ (Khmer):**

សេចក្តីជូនដំណឹងនេះមានព័ត៌មានយ៉ាងសំខាន់។ សេចក្តីជូនដំណឹងនេះប្រហែលជាមានព័ត៌មានយ៉ាងសំខាន់អំពីទម្រង់បែបបទ ឬការរៀបចំរបស់អ្នកកាមរយ: Premera Blue Cross ។ ប្រហែលជាមាន កាលបរិច្ឆេទសំខាន់នៅក្នុងសេចក្តីជូនដំណឹងនេះ។ អ្នកប្រហែលជាត្រូវការបញ្ជាក់សមត្ថភាព ដល់កិច្ចការផ្ទៃក្នុងដូចជា ធានា ដើម្បីនឹងរក្សាទុកការធានារ៉ាប់រងអនាគតរបស់អ្នក ឬប្រាក់ជំនួយចេញថ្លៃ។ អ្នកមានសិទ្ធិទទួលបានព័ត៌មាននេះ និងជំនួយនៅក្នុងភាសារបស់អ្នកដោយមិនអស់លុយឡើយ។ សូមទូរស័ព្ទ 800-722-1471 (TTY: 800-842-5357)។

**ਪੰਜਾਬੀ (Punjabi):**

ਇਸ ਨੋਟਿਸ ਵਿਚ ਖਾਸ ਜਾਣਕਾਰੀ ਹੈ. ਇਸ ਨੋਟਿਸ ਵਿਚ Premera Blue Cross ਵਲੋਂ ਤੁਹਾਡੀ ਕਵਰੇਜ ਅਤੇ ਅਰਜੀ ਬਾਰੇ ਮਹੱਤਵਪੂਰਨ ਜਾਣਕਾਰੀ ਹੋ ਸਕਦੀ ਹੈ . ਇਸ ਨੋਟਿਸ ਨਵ ਖਾਸ ਤਾਰੀਖਾਂ ਹੋ ਸਕਦੀਆਂ ਹਨ. ਜੇਕਰ ਤੁਸੀਂ ਜਸਰਤ ਕਵਰੇਜ ਰਿੱਖਣੀ ਹੋਵੇ ਜਾਂ ਓਸ ਦੀ ਲਾਗਤ ਜਵਿੱਚ ਮਦਦ ਦੇ ਇਛੁੱਕ ਹੋ ਤਾਂ ਤੁਹਾਨੂੰ ਅੰਤਮ ਤਾਰੀਖ ਤੋਂ ਪਹਿਲਾਂ ਢੁੱਝ ਖਾਸ ਕਰਮ ਚੁੱਕਣ ਦੀ ਲੋੜ ਹੋ ਸਕਦੀ ਹੈ ,ਤੁਹਾਨੂੰ ਮੁਫਤ ਵਿੱਚ ਤੋਂ ਅਪਣੀ ਭਾਸ਼ਾ ਵਿੱਚ ਜਾਣਕਾਰੀ ਅਤੇ ਮਦਦ ਪ੍ਰਾਪਤ ਕਰਨ ਦਾ ਅਧਿਕਾਰ ਹੈ ,ਕਾਲ 800-722-1471 (TTY: 800-842-5357).

**فارسی (Farsi):**

این اعلامیه حاوی اطلاعات مهم میباشد. این اعلامیه ممکن است حاوی اطلاعات مهم درباره فرم تقاضا و یا پوشش بیمه ای شما از طریق Premera Blue Cross باشد. به تاریخ های مهم در این اعلامیه توجه نمایید. شما ممکن است برای حفظ پوشش بیمه تان یا کمک در پرداخت هزینه های درمانی تان، به تاریخ های مشخصی برای انجام کارهای خاصی احتیاج داشته باشید. شما حق این را دارید که این اطلاعات و کمک را به زبان خود به طور رایگان دریافت نمایید. برای کسب اطلاعات با شماره 800-722-1471 (کلیران TTY تماس باشماره 800-842-5357) تماس برقرار نمایید.

**Polskie (Polish):**

To ogłoszenie może zawierać ważne informacje. To ogłoszenie może zawierać ważne informacje odnośnie Państwa wniosku lub zakresu świadczeń poprzez Premera Blue Cross. Prosimy zwrócić uwagę na kluczowe daty, które mogą być zawarte w tym ogłoszeniu aby nie przekroczyć terminów w przypadku utrzymania polisy ubezpieczeniowej lub pomocy związanej z kosztami. Macie Państwo prawo do bezpłatnej informacji we własnym języku. Zadzwońcie pod 800-722-1471 (TTY: 800-842-5357).

**Português (Portuguese):**

Este aviso contém informações importantes. Este aviso poderá conter informações importantes a respeito de sua aplicação ou cobertura por meio do Premera Blue Cross. Poderão existir datas importantes neste aviso. Talvez seja necessário que você tome providências dentro de determinados prazos para manter sua cobertura de saúde ou ajuda de custos. Você tem o direito de obter esta informação e ajuda em seu idioma e sem custos. Ligue para 800-722-1471 (TTY: 800-842-5357).

**Română (Romanian):**

Prezenta notificare conține informații importante. Această notificare poate conține informații importante privind cererea sau acoperirea asigurării dumneavoastră de sănătate prin Premera Blue Cross. Pot exista date cheie în această notificare. Este posibil să fie nevoie să acționați până la anumite termene limită pentru a vă menține acoperirea asigurării de sănătate sau asistența provizorie la costuri. Aveți dreptul de a obține gratuit aceste informații și ajutor în limba dumneavoastră. Sunați la 800-722-1471 (TTY: 800-842-5357).

**Русский (Russian):**

Настоящее уведомление содержит важную информацию. Это уведомление может содержать важную информацию о вашем заявлении или страховом покрытии через Premera Blue Cross. В настоящем уведомлении могут быть указаны ключевые даты. Вам, возможно, потребуется принять меры к определенным предельным срокам для сохранения страхового покрытия или помощи с расходами. Вы имеете право на бесплатное получение этой информации и помощь на вашем языке. Звоните по телефону 800-722-1471 (TTY: 800-842-5357).

**Fa'asamoa (Samoan):**

Atonu ua iai i lenei fa'asilasilaga ni fa'amatalaga e sili ona taua e tatau ona e malamalama i ai. O lenei fa'asilasilaga o se fesoasoani e fa'amatala atili i ai i le tulaga o le polokalame, Premera Blue Cross, ua e tau fia maua atu i ai. Fa'amolemole, ia e iloilo fa'alelei i aso fa'apitoa olo'o iai i lenei fa'asilasilaga taua. Masalo o le'a iai ni feau e tatau ona e faia ao le'i aulia le aso ua ta'ua i lenei fa'asilasilaga ina ia e iai pea ma maua fesoasoani mai ai i le polokalame a le Malo olo'o e iai i ai. Olo'o iai iate oe le aia tatau e maua atu i lenei fa'asilasilaga ma lenei fa'matalaga i legagana e te malamalama i ai aunoa ma se togiga tupe. Vili atu i le telefoni 800-722-1471 (TTY: 800-842-5357).

**Español (Spanish):**

Este Aviso contiene información importante. Es posible que este aviso contenga información importante acerca de su solicitud o cobertura a través de Premera Blue Cross. Es posible que haya fechas clave en este aviso. Es posible que deba tomar alguna medida antes de determinadas fechas para mantener su cobertura médica o ayuda con los costos. Usted tiene derecho a recibir esta información y ayuda en su idioma sin costo alguno. Llame al 800-722-1471 (TTY: 800-842-5357).

**Tagalog (Tagalog):**

Ang Paunawa na ito ay naglalaman ng mahalagang impormasyon tungkol sa iyong aplikasyon o pagsakop sa pamamagitan ng Premera Blue Cross. Maaaring may mga mahalagang petsa dito sa paunawa. Maaring mangailangan ka na magsagawa ng hakbang sa ilang mga itinakdang panahon upang mapanatili ang iyong pagsakop sa kalusugan o tulong na walang gastos. May karapatan ka na makakuha ng ganiitong impormasyon at tulong sa iyong wika ng walang gastos. Tumawag sa 800-722-1471 (TTY: 800-842-5357).

**ไทย (Thai):**

ประกาศนี้มีข้อมูลสำคัญ ประกาศนี้อาจมีข้อมูลที่สำคัญเกี่ยวกับกาการสมัครหรือขอบเขตประกันสุขภาพของคุณผ่าน Premera Blue Cross และอาจมีกำหนดการในประกาศนี้ คุณอาจจะต้องดำเนินการภายในกำหนดระยะเวลาที่แน่นอนเพื่อจะรักษาการประกันสุขภาพของคุณหรือการช่วยเหลือที่มีค่าใช้จ่าย คุณมีสิทธิที่จะได้รับข้อมูลและความช่วยเหลือนี้ในภาษาของคุณโดยไม่มีค่าใช้จ่าย โทร 800-722-1471 (TTY: 800-842-5357)

**Український (Ukrainian):**

Це повідомлення містить важливу інформацію. Це повідомлення може містити важливу інформацію про Ваше звернення щодо страховального покриття через Premera Blue Cross. Зверніть увагу на ключові дати, які можуть бути вказані у цьому повідомленні. Існує імовірність того, що Вам треба буде здійснити певні кроки у конкретні кінцеві строки для того, щоб зберегти Ваше медичне страхування або отримати фінансову допомогу. У Вас є право на отримання цієї інформації та допомоги безкоштовно на Вашій рідній мові. Дзвоніть за номером телефону 800-722-1471 (TTY: 800-842-5357).

**Tiếng Việt (Vietnamese):**

Thông báo này cung cấp thông tin quan trọng. Thông báo này có thông tin quan trọng về đơn xin tham gia hoặc hợp đồng bảo hiểm của quý vị qua chương trình Premera Blue Cross. Xin xem ngày quan trọng trong thông báo này. Quý vị có thể phải thực hiện theo thông báo đúng trong thời hạn để duy trì bảo hiểm sức khỏe hoặc được trợ giúp thêm về chi phí. Quý vị có quyền được biết thông tin này và được trợ giúp bằng ngôn ngữ của mình miễn phí. Xin gọi số 800-722-1471 (TTY: 800-842-5357).